Sanofi (SNY) News
NASDAQ: SNYHealth CareBiotechnology: Pharmaceutical PreparationsUSD
40.07-0.16 (-0.40%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
SNY news summary
We found 23 recent headlines mentioning Sanofi (SNY): 1 in the past week and 19 in the past 30 days, most often from Nasdaq, Seeking Alpha. For price context, SNY is down 0.40% at $40.07. The most recent story, "State attorneys general sue RFK Jr., seeking to reinstate childhood vaccine schedule", was published by Seeking Alpha on Oct 6, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Sanofi headlines
- State attorneys general sue RFK Jr., seeking to reinstate childhood vaccine scheduleSeeking Alpha
- Sanofi, Regeneron Expand Immunology Alliance With New AntibodiesSNY and REGN expand their longstanding alliance to four new antibodies targeting type II inflammation, with billions in potential payments.NasdaqREGN, SNY, AZN
- Regeneron And Sanofi Announce A Win-Win Collaboration ExpansionSeeking Alpha
- Sanofi, Regeneron Expand DUPIXENT Alliance in Deal Worth Up to €8 BillionGiants Costco, Sanofi, and SAP Raise Dividends by Over 10%Regeneron and Sanofi (NASDAQ:SNY) announced an expanded collaboration focused on developing next-generation medicines for type 2 inflammatory…Nasdaq
- Sanofi, Regeneron Expand Immunology Alliance In Deal Worth Up To $8 Bln(RTTNews) - Sanofi (SNY) and Regeneron Pharmaceuticals (REGN) on Thursday announced an expanded global collaboration to develop and commercialise four next-generation, long-acting immunology…NasdaqREGN, SNY
- Sanofi & Regeneron Expand Alliance With Four Next-Gen Antibodies(RTTNews) - On Thursday, Sanofi (SNY) and Regeneron Pharmaceuticals (REGN) announced the expansion of their global collaboration to develop and commercialize four next-generation, long-acting…NasdaqREGN, SNY
- Teva's Branded Drugs Take Center Stage in Its Growth StrategyTeva's branded drugs are driving stronger growth as Austedo, Ajovy and Uzedy gain momentum and its pipeline of new candidates expands.NasdaqTEVA, SNY, AMRN, ACIU
- GSK vs. SNY: Which Europe-Based Pharma Stock Has More Potential?GSK and Sanofi offer distinct growth drivers, but stronger earnings estimates, Dupixent momentum and a lower valuation are putting one European drugmaker in focus.NasdaqSNY, GSK, REGN
- Sanofi's New Drugs Poised to Drive Growth Beyond DupixentSNY's new drugs are gaining momentum, with Altuviiio, Ayvakit and Sarclisa poised to broaden growth beyond Dupixent.NasdaqSNY, REGN, AZN, LLY
- Is Regeneron Stock a Bargain Below $800?Key PointsRegeneron's latest financial results were strong.NasdaqREGN, SNY
- Sanofi (SAN:CA) Presents at Bank of America Global Healthcare Conference 2026 TranscriptSeeking AlphaSNY, BAC
- MRNA Hits 52-Week High: How Melanoma Study Results Keep Rally GoingModerna's 52-week high follows positive melanoma results, with detailed phase III data set for an ESMO presentation.NasdaqMRNA, SNY, PFE, MRK
- Sanofi Reviews Pipeline, Broadens Deal Hunt as It Rebuilds Research EngineGiants Costco, Sanofi, and SAP Raise Dividends by Over 10%Sanofi (NASDAQ:SNY) is reviewing its late-stage pipeline, broadening its business-development lens and working to rebuild early research…Nasdaq
- Sanofi Eyes €25B Dupixent Future, Expands M&A Hunt Ahead of Patent LossGiants Costco, Sanofi, and SAP Raise Dividends by Over 10%Sanofi (NASDAQ:SNY) is prioritizing continued growth in Specialty Care while preparing for the loss of exclusivity of Dupixent in the early…Nasdaq
- Is CRBP a Good Cannabis Investment After Positive Obesity Study Data?Corbus Pharmaceuticals' positive obesity data boosts its cannabinoid strategy, while CRB-701 and cash needs add key context for investors.NasdaqCRBP, SNY, NVO, LLY
- Bavarian Nordic Appoints Stenvall As President & CEO(RTTNews) - Danish biopharmaceutical company Bavarian Nordic A/S (BAVA.CO) on Thursday announced the appointment of Tarja Stenvall as President and Chief Executive Officer, effective October 15, 2026.NasdaqAZN, PFE, SNY
- Sanofi's C$925M Facility To Support 2027-28 Flu Vaccine Season(RTTNews) - Sanofi (SNY) announced the inauguration of the Charles Best Building, a new influenza vaccine manufacturing facility in Toronto, Canada, following a C$925 million investment to expand the…Nasdaq
- Sanofi: Stronger Launches And A New R&D Reset Keep The Re-Rating Case AliveSeeking Alpha
- Sanofi (SAN:CA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeeking AlphaSNY, MS
- Sanofi: Trump's Vaccine Policy Won't Break The StorySeeking Alpha
- Sanofi 2026 Q2 - Results - Earnings Call PresentationSeeking Alpha
- Sanofi: How I Leveraged This Undervalued Dividend AristocratSeeking Alpha
- Sanofi (SAN:CA) Q2 2026 Earnings Call TranscriptSeeking Alpha